{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:28:28Z","timestamp":1773422908097,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s10120-022-01351-4","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T19:03:06Z","timestamp":1668193386000},"page":"108-115","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A multi-institutional study to evaluate the feasibility of next-generation sequencing and genomic analysis using formalin-fixed, paraffin-embedded biopsies of gastric cancer"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5464-3819","authenticated-orcid":false,"given":"Mitsuro","family":"Kanda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yabusaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Kodera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"key":"1351_CR1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635\u201348.","journal-title":"Lancet"},{"key":"1351_CR2","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-020-01251-0","volume":"19","author":"M Kanda","year":"2020","unstructured":"Kanda M, Shimizu D, Sawaki K, Nakamura S, Umeda S, Miwa T, et al. Therapeutic monoclonal antibody targeting of neuronal pentraxin receptor to control metastasis in gastric cancer. Mol Cancer. 2020;19:131.","journal-title":"Mol Cancer"},{"key":"1351_CR3","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.20.02914","volume":"39","author":"YK Kang","year":"2021","unstructured":"Kang YK, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, et al. PRODIGY: a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol. 2021;39:2903\u201313.","journal-title":"J Clin Oncol"},{"key":"1351_CR4","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(21)00297-7","volume":"22","author":"X Zhang","year":"2021","unstructured":"Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22:1081\u201392.","journal-title":"Lancet Oncol"},{"key":"1351_CR5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jcmgh.2017.01.003","volume":"3","author":"BW Katona","year":"2017","unstructured":"Katona BW, Rustgi AK. Gastric cancer genomics: advances and future directions. Cell Mol Gastroenterol Hepatol. 2017;3:211\u20137.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"1351_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-03944-z","author":"K Kleo","year":"2022","unstructured":"Kleo K, Jovanovic VM, Arndold A, Lehmann A, Lammert H, Berg E, et al. Response prediction in patients with gastric and esophagogastric adenocarcinoma under neoadjuvant chemotherapy using targeted gene expression analysis and next-generation sequencing in pre-therapeutic biopsies. J Cancer Res Clin Oncol. 2022. https:\/\/doi.org\/10.1007\/s00432-022-03944-z.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1351_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jss.2017.06.077","volume":"220","author":"M Nagahashi","year":"2017","unstructured":"Nagahashi M, Shimada Y, Ichikawa H, Nakagawa S, Sato N, Kaneko K, et al. Formalin-fixed paraffin-embedded sample conditions for deep next generation sequencing. J Surg Res. 2017;220:125\u201332.","journal-title":"J Surg Res"},{"key":"1351_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211400","volume":"14","author":"SJ McDonough","year":"2019","unstructured":"McDonough SJ, Bhagwate A, Sun Z, Wang C, Zschunke M, Gorman JA, et al. Use of FFPE-derived DNA in next generation sequencing: DNA extraction methods. PLoS ONE. 2019;14: e0211400.","journal-title":"PLoS ONE"},{"key":"1351_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176280","volume":"12","author":"N Einaga","year":"2017","unstructured":"Einaga N, Yoshida A, Noda H, Suemitsu M, Nakayama Y, Sakurada A, et al. Assessment of the quality of DNA from various formalin-fixed paraffin-embedded (FFPE) tissues and the use of this DNA for next-generation sequencing (NGS) with no artifactual mutation. PLoS ONE. 2017;12: e0176280.","journal-title":"PLoS ONE"},{"key":"1351_CR10","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1053\/j.gastro.2021.07.012","volume":"161","author":"KG Hulten","year":"2021","unstructured":"Hulten KG, Genta RM, Kalfus IN, Zhou Y, Zhang H, Graham DY. Comparison of culture with antibiogram to next-generation sequencing using bacterial isolates and formalin-fixed paraffin-embedded gastric biopsies. Gastroenterology. 2021;161:1433-42.e2.","journal-title":"Gastroenterology"},{"key":"1351_CR11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"CGAR Network","year":"2014","unstructured":"Network CGAR. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202\u20139.","journal-title":"Nature"},{"key":"1351_CR12","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2217\/pme-2017-0011","volume":"14","author":"C Eifert","year":"2017","unstructured":"Eifert C, Pantazi A, Sun R, Xu J, Cingolani P, Heyer J, et al. Clinical application of a cancer genomic profiling assay to guide precision medicine decisions. Per Med. 2017;14:309\u201325.","journal-title":"Per Med"},{"key":"1351_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13073-017-0484-3","volume":"9","author":"H Ichikawa","year":"2017","unstructured":"Ichikawa H, Nagahashi M, Shimada Y, Hanyu T, Ishikawa T, Kameyama H, et al. Actionable gene-based classification toward precision medicine in gastric cancer. Genome Med. 2017;9:93.","journal-title":"Genome Med"},{"key":"1351_CR14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10120-019-00995-z","volume":"23","author":"M Kanda","year":"2020","unstructured":"Kanda M, Suh YS, Park DJ, Tanaka C, Ahn SH, Kong SH, et al. Serum levels of ANOS1 serve as a diagnostic biomarker of gastric cancer: a prospective multicenter observational study. Gastric Cancer. 2020;23:203\u201311.","journal-title":"Gastric Cancer"},{"key":"1351_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.5230\/jgc.2019.19.e25","volume":"19","author":"J Jeon","year":"2019","unstructured":"Jeon J, Cheong JH. Clinical implementation of precision medicine in gastric cancer. J Gastric Cancer. 2019;19:235\u201353.","journal-title":"J Gastric Cancer"},{"key":"1351_CR16","doi-asserted-by":"publisher","first-page":"4419","DOI":"10.1038\/s41598-022-08430-7","volume":"12","author":"H Hirano","year":"2022","unstructured":"Hirano H, Abe Y, Nojima Y, Aoki M, Shoji H, Isoyama J, et al. Temporal dynamics from phosphoproteomics using endoscopic biopsy specimens provides new therapeutic targets in stage IV gastric cancer. Sci Rep. 2022;12:4419.","journal-title":"Sci Rep"},{"key":"1351_CR17","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.3390\/biomedicines10071614","volume":"10","author":"Y Sato","year":"2022","unstructured":"Sato Y, Okamoto K, Kawaguchi T, Nakamura F, Miyamoto H, Takayama T. Treatment response predictors of neoadjuvant therapy for locally advanced gastric cancer: current status and future perspectives. Biomedicines. 2022;10:1614.","journal-title":"Biomedicines."},{"key":"1351_CR18","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/nrgastro.2014.143","volume":"11","author":"MH McLean","year":"2014","unstructured":"McLean MH, El-Omar EM. Genetics of gastric cancer. Nat Rev Gastroenterol Hepatol. 2014;11:664\u201374.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1351_CR19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00428-013-1533-y","volume":"464","author":"C Duraes","year":"2014","unstructured":"Duraes C, Almeida GM, Seruca R, Oliveira C, Carneiro F. Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? Virchows Arch. 2014;464:367\u201378.","journal-title":"Virchows Arch"},{"key":"1351_CR20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrclinonc.2014.138","volume":"11","author":"M Razzak","year":"2014","unstructured":"Razzak M. Genetics: new molecular classification of gastric adenocarcinoma proposed by The Cancer Genome Atlas. Nat Rev Clin Oncol. 2014;11:499.","journal-title":"Nat Rev Clin Oncol"},{"key":"1351_CR21","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12943-020-01219-0","volume":"19","author":"L Yuan","year":"2020","unstructured":"Yuan L, Xu ZY, Ruan SM, Mo S, Qin JJ, Cheng XD. Long non-coding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance. Mol Cancer. 2020;19:96.","journal-title":"Mol Cancer"},{"key":"1351_CR22","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1007\/s12253-020-00844-w","volume":"26","author":"D Niu","year":"2020","unstructured":"Niu D, Li L, Yu Y, Zang W, Li Z, Zhou L, et al. Evaluation of next generation sequencing for detecting HER2 copy number in breast and gastric cancers. Pathol Oncol Res. 2020;26:2577\u201385.","journal-title":"Pathol Oncol Res"},{"key":"1351_CR23","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1111\/1759-7714.14411","volume":"13","author":"T Sakaguchi","year":"2022","unstructured":"Sakaguchi T, Nishii Y, Iketani A, Esumi S, Esumi M, Furuhashi K, et al. Comparison of the analytical performance of the Oncomine dx target test focusing on bronchoscopic biopsy forceps size in non-small cell lung cancer. Thorac Cancer. 2022;13:1449\u201356.","journal-title":"Thorac Cancer"},{"key":"1351_CR24","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1158\/2159-8290.CD-21-0219","volume":"11","author":"M Kwon","year":"2021","unstructured":"Kwon M, An M, Klempner SJ, Lee H, Kim KM, Sa JK, et al. Determinants of response and intrinsic resistance to PD-1 blockade in microsatellite instability-high gastric cancer. Cancer Discov. 2021;11:2168\u201385.","journal-title":"Cancer Discov"},{"key":"1351_CR25","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41571-021-00492-2","volume":"18","author":"Y Nakamura","year":"2021","unstructured":"Nakamura Y, Kawazoe A, Lordick F, Janjigian YY, Shitara K. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. Nat Rev Clin Oncol. 2021;18:473\u201387.","journal-title":"Nat Rev Clin Oncol"},{"key":"1351_CR26","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-22-0121","volume":"28","author":"KW Lee","year":"2022","unstructured":"Lee KW, Van Cutsem E, Bang YJ, Fuchs CS, Kudaba I, Garrido M, et al. Association of tumor mutational burden with efficacy of pembrolizumab\u00b1chemotherapy as first-line therapy for gastric cancer in the phase III KEYNOTE-062 study. Clin Cancer Res. 2022;28:3489\u201398.","journal-title":"Clin Cancer Res"},{"key":"1351_CR27","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamaoncol.2016.6762","volume":"3","author":"EC Smyth","year":"2017","unstructured":"Smyth EC, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z, et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the medical research council adjuvant gastric infusional chemotherapy (MAGIC) trial. JAMA Oncol. 2017;3:1197\u2013203.","journal-title":"JAMA Oncol"},{"key":"1351_CR28","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/SLA.0000000000002803","volume":"270","author":"YY Choi","year":"2019","unstructured":"Choi YY, Kim H, Shin SJ, Kim HY, Lee J, Yang HK, et al. Microsatellite instability and programmed cell death-ligand 1 expression in stage II\/III gastric cancer: post hoc analysis of the classic randomized controlled study. Ann Surg. 2019;270:309\u201316.","journal-title":"Ann Surg"},{"key":"1351_CR29","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/cas.14798","volume":"112","author":"K Akagi","year":"2021","unstructured":"Akagi K, Oki E, Taniguchi H, Nakatani K, Aoki D, Kuwata T, et al. The real-world data on microsatellite instability status in various unresectable or metastatic solid tumors. Cancer Sci. 2021;112:1105\u201313.","journal-title":"Cancer Sci"},{"key":"1351_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.07.042","author":"M Hirabayashi","year":"2022","unstructured":"Hirabayashi M, Georges D, Clifford GM, de Martel C. Estimating the global burden of Epstein\u2013Barr virus associated gastric cancer: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022. https:\/\/doi.org\/10.1016\/j.cgh.2022.07.042.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1351_CR31","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.omtn.2020.10.001","volume":"22","author":"M Kanda","year":"2020","unstructured":"Kanda M, Kasahara Y, Shimizu D, Miwa T, Umeda S, Sawaki K, et al. Amido-bridged nucleic acid-modified antisense oligonucleotides targeting SYT13 to treat peritoneal metastasis of gastric cancer. Mol Ther Nucleic Acids. 2020;22:791\u2013802.","journal-title":"Mol Ther Nucleic Acids"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-022-01351-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-022-01351-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-022-01351-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T01:04:52Z","timestamp":1699664692000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-022-01351-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1351"],"URL":"https:\/\/doi.org\/10.1007\/s10120-022-01351-4","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,11]]},"assertion":[{"value":"23 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A potential conflict of interest exists because DENKA Corporation performed the cancer panel analysis (CANCERPLEX-JP) free of charge. However, only anonymized identification numbers for all samples were disclosed, and all medical information including age and gender were masked. This prevented the results of the cancer panel analysis from being represented as favorable to DENKA Corporation, which had no influence on the planning, implementation, and results of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures were in accordance with the ethical standards of the responsible committees on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent for the JCOG1509 trial and the present study was obtained from all patients as required by the Institutional Review Board of each participating institution.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}